ALZ-801/valiltramiprosate, an oral agent that blocks the misfolding of amyloid monomers and the formation of all soluble amyloid aggregates [59], has shown positive biomarker effects and promising efficacy in APOE4 carrier early AD patients [2,26,58] without increasing the risk of ARIA [26,58]. Here, APOE is linked to Alzheimer disease.